

C. SERENI¹, L. MALJEAN¹, F. MOREY¹, S. DUPIRE², B. MAUGUEN¹

¹ CENTRE HOSPITALIER DE BOURG-EN-BRESSE, PHARMACY, BOURG-EN-BRESSE, France

² CENTRE HOSPITALIER DE BOURG-EN-BRESSE, ONCOLOGY-HEMATOLOGY DEPARTMENT, BOURG-EN-BRESSE, France

BACKGROUND & IMPORTANCE

Daratumumab is anti-CD38 monoclonal antibody now extensively used for multiple myeloma. Due to the high risk of Infusion-Related Reactions (IRRs), it is administered over a period of 4 hours. The French Myeloma Intergroup, as part of the Covid-19 outbreak, has authorized infusions of Daratumumab in 1.5 hours in clinical trials (CT) based on studies showing a safety profile comparable to long infusions.

AIM & OBJECTIF

The aim of this study was to evaluate IRRs associated with rapid injection of daratumumab in a real-life population.


From June to July 2020




A training course was organized by the pharmacy department




Patient who received



**Rapid Daratumumab
(infusion in 1.5 hours)**



To present the new infusion rate
+
Safety reminders on IRRs and their monitoring



At least **2 or more doses**
of daratumumab

+

Data collected

- Age, sex, comorbidities
- Previous daratumumab
- Treatment protocol



Standard infusion rate




IRRs were directly recorded in validation-administration software



Patient profile

Age

Average : 69.5 years old



Sex



35%




65%





Co-morbidities

65,2% the patients had at least one co-morbidity



Type of treatments




Dara 1h30

23 Patients

0
IRRs

Number of previous perfusions



■ 3 -10 perfusions ■ 10 -20 perfusions ■ > 20 perfusions

No IRRs were experienced during our study

These findings suggest that Rapid Daratumumab:

- Safe as Daratumumab standard perfusion rate
- Less expensive than subcutaneous Daratumumab
- Decrease time infusion

- Reduced time contact & hospitalization during Covid-19 outbreak

- Optimize nurse's time